Showing 4461-4470 of 8581 results for "".
- Marketing Exec Lizette Williams Joins RealSelf’s Boardhttps://practicaldermatology.com/news/lizette-williams-global-head-of-vertical-solutions-marketing-at-facebook-joins-realselfs-board/2460540/Marketing and advertising executive Lizette Williams is the newest member of RealSelf’s Board of Directors. Ms. Williams serves as the Global Head of Vertical Solutions Marketing at Facebook. Prior to Facebook she has worked in major marketing roles at McDonald's, Kimberl
- Tattoos Impair Sweating, May Increase Risk of Heat-related Injuryhttps://practicaldermatology.com/news/tattoos-impair-sweating-may-increase-risk-of-heat-related-injury/2460539/New research finds that tattooed skin does not sweat as much as non-inked areas, which may have implications for the body’s ability to cool in people with extensive tattooing.
- Suneva to Market and Distribute Neauvia's Plasma IQ in North Americahttps://practicaldermatology.com/news/suneva-to-market-and-distribute-neauvias-plasma-iq-in-north-america/2460534/Suneva Medical, Inc., will market and distribute Neauvia Plasma IQ throughout North America as part of a new partnership. The first Class 2 FDA-cleared plasma energy device, Plasma IQ delivers focused, controlled plasma energy to create microinjuries on the skin, renewing
- Medimetriks Streamlines MM36 AD Development Programhttps://practicaldermatology.com/news/medimetriks-streamlines-mm36-ad-development-program/2460532/Medimetriks Pharmaceuticals, Inc. is moving forward with its MM36 (difamilast) Atopic Dermatitis Development Program following a meeting with the U.S. Food and Drug Administration (FDA). Medimetriks is now preparing to conduct a s
- Partner Therapeutics Moves Ahead with Phase 3 Study of Leukine Plus Ipilumimab and Nivolumab for Melanomahttps://practicaldermatology.com/news/partner-therapeutics-moves-ahead-with-phase-3-study-of-leukine-plus-ipilumimab-and-nivolumab-for-melanoma/2460524/Partner Therapeutics, Inc. is resuming enrollment in the National Cancer Institute (NCI)-sponsored ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) study of Leukine plus Ipilumimab and Nivolumab for Melanoma following a successful planned interim analysis. EA6141 (
- ICYMI: ASA Honors Drs. Doris Day and Mark Lebwohl at Virtual Galahttps://practicaldermatology.com/news/icymi-asa-honors-drs-doris-day-and-mark-lebwohl-at-virtual-gala/2460521/Dermatologists Drs. Doris Day and Mark Lebwohl took home top awards at the American Skin Association’s (ASA) annual gala, which was held virtually this year. Dr. Day, a clinical associate professor of dermatology at NYU Langone Medical Center, received ASA's Excellen
- Medicine X Launches Eczema Xplained Patient Story To Drive Understanding and Awareness of ADhttps://practicaldermatology.com/news/medicine-x-launches-eczema-xplained-patient-story-to-drive-understanding-and-awareness-of-ad/2460519/Medicine X today is launching Eczema Xplained, its first illustrated story in the U.S. on atopic dermatitis, the most comm
- MC2 Partners with EPI for Commercialization of Wynzorahttps://practicaldermatology.com/news/mc2-partners-partners-with-epi-for-commercialization-of-wynzora/2460510/MC2 Therapeutics has entered a Collaboration Agreement with EPI Health, LLC on the commercialization of Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the US. Wynzora Cream was approvedby the FDA last month for the topical treatment of plaque psoriasis in adult
- Verrica Pharmaceuticals Names New Clinical and Drug Development Leadership Team Membershttps://practicaldermatology.com/news/verrica-pharmaceuticals-names-new-clinical-and-drug-development-leadership-team-members/2460509/Verrica Pharmaceuticals Inc. announced key appointments to its drug development team. Current Board of Directors member Gary Goldenberg, MD, a thought leader in the field of dermatology, stepped down to become Verrica’s Chief Medical Officer, effective August 1, 2020. Dr. Law
- InMode Introduces the Morpheus8 Platform and the Morpheus8 Body Fractional Technologyhttps://practicaldermatology.com/news/inmode-introduces-the-morpheus8-platform-and-the-morpheus8-body-fractional-technology/2460501/InMode Ltd. is introducing the Morpheus8 Body handpiece and Morpheus8 Platform. Morpheus8 Body is a full-body fractional technology that delivers RF energy up to a thermal depth of 8mm (7mm pin depth + an additional 1mm thermal profile), with its